Abstract
The synthesis of two new sulfated xanthones and two O-substituted benzophenones was carried out to evaluate for their inhibitory effect on growth of human tumor cell lines. The sulfation of 3,6-(2) and 3,4-dihydroxyxanthone (3) was accomplished using sulfur trioxide-pyridine to give, respectively, xanthone-3,6-O,O-bis(sulfate) (4) and xanthone- 3,4-O,O-bis(sulfate) (5). Treatment of 2,2,4,4-tetrahydroxybenzophenone (6) with acetic acid and prenyl bromide furnished 2,2,4,4- tetraacetoxybenzophenone (7) and (5-hydroxy-2,2-dimethylchroman-6-yl)(2-hydroxy-4-(tertpentyloxy) phenyl)methanone (8), respectively. Compounds 2-8 were tested for their effect on the in vitro growth of four representative human tumor cell lines: MCF-7 ER(+) (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), SF-268 (glioma), and A375-C5 (melanoma). Compounds 2 and 7-8 showed an inhibitory activity in the μM range.`
Keywords: Antitumor, Benzophenones, Prenylated, Sulfated, Xanthones
Letters in Drug Design & Discovery
Title: Synthesis of Xanthones and Benzophenones as Inhibitors of Tumor Cell Growth
Volume: 7 Issue: 7
Author(s): Elisangela Costa, Emilia Sousa, Nair Nazareth, Maria S.J. Nascimento and Madalena M.M. Pinto
Affiliation:
Keywords: Antitumor, Benzophenones, Prenylated, Sulfated, Xanthones
Abstract: The synthesis of two new sulfated xanthones and two O-substituted benzophenones was carried out to evaluate for their inhibitory effect on growth of human tumor cell lines. The sulfation of 3,6-(2) and 3,4-dihydroxyxanthone (3) was accomplished using sulfur trioxide-pyridine to give, respectively, xanthone-3,6-O,O-bis(sulfate) (4) and xanthone- 3,4-O,O-bis(sulfate) (5). Treatment of 2,2,4,4-tetrahydroxybenzophenone (6) with acetic acid and prenyl bromide furnished 2,2,4,4- tetraacetoxybenzophenone (7) and (5-hydroxy-2,2-dimethylchroman-6-yl)(2-hydroxy-4-(tertpentyloxy) phenyl)methanone (8), respectively. Compounds 2-8 were tested for their effect on the in vitro growth of four representative human tumor cell lines: MCF-7 ER(+) (breast adenocarcinoma), NCI-H460 (non-small cell lung cancer), SF-268 (glioma), and A375-C5 (melanoma). Compounds 2 and 7-8 showed an inhibitory activity in the μM range.`
Export Options
About this article
Cite this article as:
Costa Elisangela, Sousa Emilia, Nazareth Nair, S.J. Nascimento Maria and M.M. Pinto Madalena, Synthesis of Xanthones and Benzophenones as Inhibitors of Tumor Cell Growth, Letters in Drug Design & Discovery 2010; 7 (7) . https://dx.doi.org/10.2174/157018010791526250
DOI https://dx.doi.org/10.2174/157018010791526250 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Indoleamine 2,3-Dioxygenase, an Emerging Target for Anti-Cancer Therapy
Current Cancer Drug Targets Wnt/β-catenin Antagonists: Exploring New Avenues to Trigger Old Drugs in Alleviating Glioblastoma Multiforme
Current Molecular Pharmacology Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis
Current Cancer Therapy Reviews Cancer Stem Cells Equipped with Powerful Hedgehog Signaling and Better Epigenetic Memory: Avenues to Look for Cancer Therapeutics
Current Cancer Drug Targets Advances in Drug Delivery from Nose to Brain: An Overview
Current Drug Therapy Current Developments in Targeted Drug Delivery Systems for Glioma
Current Pharmaceutical Design Current Limitations in the Treatment of Parkinson’s and Alzheimer’s Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers
Current Medicinal Chemistry Targeted Oncolytic Herpes Simplex Viruses for Aggressive Cancers
Current Pharmaceutical Biotechnology Effect of miR-128 in DNA Damage of HL-60 Acute Myeloid Leukemia Cells
Current Pharmaceutical Biotechnology The Current Role of PET/CT in Radiotherapy Planning
Current Radiopharmaceuticals Targeting the Akt Kinase to Modulate Survival, Invasiveness and Drug Resistance of Cancer Cells
Current Medicinal Chemistry Possibility of Non-Immunosuppressive Immunophilin Ligands as Potential Therapeutic Agents for Parkinsons Disease
Current Pharmaceutical Design Metal Based Frameworks for Drug Delivery Systems
Current Topics in Medicinal Chemistry Targeting Brain Tumors with Nanomedicines: Overcoming Blood Brain Barrier Challenges
Current Clinical Pharmacology The Role of PEDF in Tumor Growth and Metastasis
Current Molecular Medicine Meet Our Editorial Board Member
Letters in Drug Design & Discovery Novel Targeting of Apoptosis Pathways for Prostate Cancer Therapy
Current Cancer Drug Targets Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design Nitroimidazole Radiopharmaceuticals in Bioimaging: Part I: Synthesis and Imaging Applications
Current Radiopharmaceuticals MiRNA-145 and Its Direct Downstream Targets in Digestive System Cancers: A Promising Therapeutic Target
Current Pharmaceutical Design